Key result
Perioperative management of antiplatelet therapy should be individually tailored to minimize ischemic and bleeding risks, ideally delaying surgery 3-6 months from the index cardiac event.
Why the study?
Perioperative management of antiplatelet agents in noncardiac surgery remains controversial regarding the balance between bleeding and thrombotic risks.
How does the continuation versus discontinuation of antiplatelet therapy impact ischemic events, bleeding, and mortality in patients undergoing noncardiac surgery?
How does the continuation versus discontinuation of antiplatelet therapy impact ischemic events, bleeding, and mortality in patients undergoing noncardiac surgery?
Perioperative management of antiplatelet therapy in noncardiac surgery requires an individualized, multidisciplinary approach balancing bleeding and thrombotic risks.
Answers are grounded in this paper and cite their sources.
May support individualized perioperative antiplatelet decisions; leaves open optimal timing from randomized trials.
PURPOSE OF REVIEW: Perioperative management of antiplatelet agents (APAs) in the setting of noncardiac surgery is a controversial topic of balancing bleeding versus thrombotic risks. RECENT FINDINGS: Recent data do not support a clear association between continuation or discontinuation of APAs and rates of ischemic events, bleeding complications, and mortality up to 6 months after surgery. Clinical factors, such as indication and urgency of the operation, time since stent placement, invasiveness of the procedure, preoperative cardiac optimization, underlying functional status, as well as perioperative control of supply-demand mismatch and bleeding may be more responsible for adverse outcome than antiplatelet management. SUMMARY: Perioperative management of antiplatelet therapy (APT) should be individually tailored based on consensus among the anesthesiologist, cardiologist, surgeon, and patient to minimize both ischemic/thrombotic and bleeding risks. Where possible, surgery should be delayed for a minimum of 1 month but ideally for 3-6 months from the index cardiac event. If bleeding risk is acceptable, dual APT (DAPT) should be continued perioperatively; otherwise P2Y12 inhibitor therapy should be discontinued for the minimum amount of time possible and aspirin monotherapy continued. If bleeding risk is prohibitive, both aspirin and P2Y12 inhibitor therapy should be interrupted and bridging therapy may be considered in patients with high thrombotic risk.
No takes yet. Share an insight, caveat, or question.
Filipescu et al. (2020) conducted a review in Patients on antiplatelet therapy undergoing noncardiac surgery. Perioperative management of antiplatelet therapy was evaluated. Perioperative management of antiplatelet therapy should be individually tailored to minimize ischemic and bleeding risks, ideally delaying surgery 3-6 months from the index cardiac event.
Synapse has enriched 10 related papers. Consider them for comparative context: